Evaluating the Safety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-CelT), a Novel Humanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B